New alpha therapy shows promise for Tough-to-Treat prostate cancer
NCT ID NCT05219500
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This phase II trial tests a new drug called FPI-2265 for men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug delivers a powerful radioactive particle directly to cancer cells. The main goal is to see if it can lower PSA levels by at least 50% in the first 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas, 77042, United States
-
XCancer Omaha/Urology Cancer Center
Omaha, Nebraska, 68130, United States
Conditions
Explore the condition pages connected to this study.